Arthur Hayes criticized Cardano's dApps for lack of utility, engaging in a heated exchange with co-founder Charles Hoskinson, while questioning ADA's value and suggesting Ethereum as a better option.
AlexSolana (SOL) exceeds Ethereum (ETH) in daily DEX volume, signaling potential rally. Arthur Hayes optimistic amid NYCB crisis. SOL trades around $99.
EdmundHayes predicts an epic Solana (SOL) rally amid potential U.S. banking crisis, adding intrigue to crypto anticipation.
Xu LinArthur Cheong advocates for a paradigm shift towards DeFi, pinpointing Synthetix (SNX), Aave, and Axie Infinity as altcoins with substantial potential. Article Summary: Renowned venture capitalist Arthur Cheong identifies top altcoin picks, emphasizing the transformative potential of DeFi. He critiques traditional fintech's lack of innovation and highlights Synthetix (SNX), Aave, and Axie Infinity as groundbreaking investments within the evolving crypto landscape. Cheong envisions a financial world organized through a different paradigm, positioning these altcoins as key players in the industry's future.
Cheng YuanArthur Hayes warns of a potential 20-30% crypto market drop in March, citing U.S. financial risks and expiring Federal Reserve facilities.
BerniceThe machine learning model developed through the collaboration between Oita University and Eisai Co. in Japan represents a significant breakthrough in Alzheimer's screening. It utilizes wristband sensor data to predict the accumulation of beta-amyloid protein. This innovative approach holds promise as a more accessible, cost-effective, and non-invasive method for early detection of Alzheimer's disease.
SanyaArthur Hayes shifts investment from Solana to Ethereum following a 'divine message'.
EdmundAstraZeneca partners with AI firm Absci in a groundbreaking $247 million venture to develop advanced cancer-fighting antibodies, marking a significant stride in AI's integration with healthcare research.
YouQuanAmid SEC challenges and cryptocurrency disputes, Coinbase CEO Brian Armstrong calls for a stronger U.S. regulatory framework.
Hui XinAstraZeneca pioneers a healthcare revolution, unveiling Evinova to accelerate clinical trials and integrate digital solutions in a new era of medical advancements.
Hui Xin